Evidence map›Paper›PMID 38507132›Full record

ArticleClinical rheumatology2024

Identification of EPSTI1 as a new potential biomarker for SLE based on GEO database.

Yiying Yang, Huali Zhang, Xiaoyu Xiao, Muyao Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Yiying YangDepartment of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huali ZhangDepartment of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaoyu XiaoDepartment of Nutrition, Xiangya Hospital, Central South University, Changsha, Hunan, China. xiaoxiaoyu0128@163.com.
Muyao GuoDepartment of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 4011394@csu.edu.cn.ORCID http://orcid.org/0000-0003-1347-0848
Central South University · CN

Funding

National Natural Science Foundation of China 81901664National Natural Science Foundation of China 82070018National Natural Science Foundation of China 82270097Natural Science Foundation of Hunan Province 2020JJ5894
6 · The paper itself

Abstract

objectiveSystemic lupus erythematosus (SLE) is a chronic autoimmune disease with highly heterogeneous. The aim of this study is to find the key genes in peripheral blood mononuclear cells (PBMCs) of SLE patients and to provide a new direction for the diagnosis and treatment of lupus.

methodsGSE121239, GSE50772, GSE81622, and GSE144390 mRNA expression profiles were obtained from the website of Gene Expression Omnibus (GEO), and differential expressed genes (DEGs) analysis was performed by R. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to elucidate signaling pathways for the DEGs. Real-time qPCR (RT-qPCR) was used to verify the key gene EPSTI1 in PBMCs of SLE patients. Finally, the correlation analysis and ROC curve analysis of EPSTI1 for SLE were performed.

resultsA total of 12 upregulated DEGs were identified, including MMP8, MX1, IFI44, EPSTI1, OAS1, OAS3, HERC5, IFIT1, RSAD2, USP18, IFI44L, and IFI27. GO and KEGG pathway enrichment analysis showed that those DEGs were mainly concentrated in the response to virus and IFN signaling pathways. Real-time qPCR (RT-qPCR) revealed that EPSTI1 was increased in PBMCs of SLE. EPSTI1 was positively correlated with SLEDAI score in SLE patients. Besides, EPSTI1 was positively correlated with T cell activation- or differentiation-associated genes (BCL6 and RORC). Furthermore, ROC analyses proved EPSTI1 may have diagnostic value for SLE.

conclusionTogether, EPSTI1 was found to be a potential biomarker for SLE, closely related to T cell immune imbalance. Key Points • EPSTI1 expression was significantly increased in PBMCs of SLE patients. • EPSTI1 was positively correlated with disease activity and T cell activation- or differentiation-associated genes in SLE patients. • EPSTI1 might have a good diagnostic value for SLE.

Indexed as

Leukocytes, MononuclearLupus Erythematosus, SystemicBiomarkersCell DifferentiationComputational BiologyHumansNeoplasm ProteinsSignal TransductionUbiquitin ThiolesteraseBiomarkersEPSTI1 protein, humanNeoplasm ProteinsUbiquitin ThiolesteraseUSP18 protein, humanBioinformatics analysisBiomarkerEPSTI1SLET cell

Identifiers

PMID38507132
OpenAlexW4393010519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.